中国全科医学2018，Vol.21Issue(6)：627-632,6.DOI:10.3969/j.issn.1007-9572.2018.00.014
《2017年ACR糖皮质激素性骨质疏松症防治指南》解读
Interpretation of 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
摘要
Abstract
Glucocorticoid-induced osteoporosis (GIOP) ranks first in secondary osteoporosis. The effect of glucocorticoids (GCs) on bone mass persists and there is no safety threshold. Therefore, prevention and treatment of GCs is always appropriate at any time. With more evidence and experience gained about clinically important features of GIOP, its fracture risk assessment and better decisions during intervention period and follow-up, the American College of Rheumatology again launched the new GIOP guidelines in 2017. This article summarized the fracture risk stratification, timing of assessment and reassessment, initial and follow-up treatment strategies for general/special populations in order to update notion of clinicians treating GIOP.关键词
骨质疏松/糖皮质激素类/骨折/指南Key words
Osteoporosis/Glucocorticoids/Fractures/bone/Guidebooks分类
医药卫生引用本文复制引用
高颖,赵东宝..《2017年ACR糖皮质激素性骨质疏松症防治指南》解读[J].中国全科医学,2018,21(6):627-632,6.基金项目
上海领军人才队伍建设专项基金(201444) （201444）
